Upstream & Downstream Process

Profacgen's Upstream & Downstream Process services provide an integrated framework for protein and biologic development, spanning early material generation, process optimization, regulatory-enabling production, and cGMP manufacturing.

Rather than presenting upstream and downstream activities as disconnected steps, Profacgen structures them as a continuous, decision-driven process, enabling efficient progression from research-grade material to regulated manufacturing.

Why an Integrated Upstream & Downstream Strategy Matters

In protein and biologics development, production challenges rarely arise from a single step. Instead, risk accumulates when:

Early material is generated without consideration for future regulatory expectations
Process knowledge is fragmented across vendors or stages
Scale-up decisions are made without comparability or documentation planning
Non-cGMP and cGMP activities are treated as unrelated efforts

An integrated upstream & downstream strategy addresses these risks by ensuring:

Continuity of process understanding
Alignment between early development and regulated manufacturing
Predictable transitions between non-cGMP, GLP, and cGMP stages
Material consistency that supports data integrity and regulatory confidence

Request an Upstream & Downstream Strategy Consultation

Our Integrated Upstream & Downstream Service Framework

Profacgen's Upstream & Downstream Process capabilities are organized into four interconnected layers, allowing services to be combined and scaled according to program stage.

Early-Stage and Specialized Material Generation

Early-stage and specialized material generation

These services support discovery, feasibility studies, functional evaluation, and early development where flexibility and speed are critical—while still maintaining documentation and reproducibility.

Custom Lysate Preparation Service

Provides tailored lysate material with controlled preparation and documentation to support functional assays, proteomics, enzymatic evaluation, and analytical workflows. Used when:

Assay performance depends on lysate consistency
Comparative or benchmarking studies are required
Off-the-shelf lysates introduce unacceptable variability

Antimicrobial Peptides Services

Supports antimicrobial peptide design, synthesis, characterization, and functional evaluation for therapeutic, diagnostic, or industrial programs.

Used when:

Peptide-based activity is central to program value
Functional benchmarking and reproducibility are required
Peptide candidates must be prioritized for downstream development

Nanozymes Production

Delivers controlled production and characterization of nanozyme materials with enzyme-like functionality. Used when:

Enzyme-mimetic activity is a key functional driver
Material consistency is required across testing cycles
Nanozyme performance must be evaluated under defined conditions

Expression, Recovery, and Process Feasibility

Expression, recovery, and process feasibility

This layer addresses how proteins are expressed, recovered, and initially purified, laying the groundwork for scalable and compliant production.

Large-Scale Protein Production

Supports scalable protein expression with controlled parameters to generate material for development, testing, or regulatory-enabling activities.

Used when:

Larger quantities of protein are required
Expression systems must support downstream scalability
Early production decisions will impact future manufacturing feasibility

Inclusion Body Purification & Protein Refolding

Provides recovery and refolding strategies for proteins expressed as inclusion bodies, with emphasis on yield recovery and functional relevance.

Used when:

Proteins exhibit insolubility during expression
Refolding is required to restore biological activity
Process feasibility must be assessed before scale-up

Enzymatic Protein Synthesis

Offers enzymatic approaches to protein synthesis where traditional expression systems may be limiting.

Used when:

Sequence complexity or modification requirements are high
Cell-based expression is inefficient or impractical
Controlled synthesis is needed for specialized applications

Quality-Driven Development and Regulatory-Enabling Production

Quality-driven development and regulatory-enabling production

This layer bridges development activities with regulatory expectations, focusing on documentation, comparability, and decision-ready material.

GLP Compliant Protein Production

Supports production of protein material under GLP-aligned quality systems for non-clinical and regulatory-relevant studies.

Used when:

Protein material supports toxicology or safety studies
Data integrity and traceability are required
Early regulatory confidence is needed without full GMP escalation

In Vitro Glyco Engineering (IVGE)

Enables controlled modification of glycosylation profiles to evaluate structure-function relationships and comparability.

Used when:

Glycosylation impacts efficacy, stability, or safety
Functional or analytical comparisons are required
Glycan control is needed prior to GMP manufacturing

IND-enabling Non-cGMP Production and cGMP Manufacturing

Provides integrated material production for IND-supporting activities while preparing for transition into regulated manufacturing.

Used when:

Preclinical material must support IND filings
Process knowledge must be preserved across stages
Seamless transition to GMP is critical for timelines

Regulated Manufacturing and Long-Term Production Strategy

Regulated manufacturing and long-term production strategy

This layer delivers compliant, scalable manufacturing aligned with regulatory and commercial objectives.

cGMP Compliant Protein Production

Provides protein manufacturing under cGMP conditions with quality systems, documentation, and release controls suitable for clinical and regulated use.

Used when:

Clinical trial material is required
Regulatory compliance is mandatory
Long-term production consistency is critical

Pharmaceutical Contract Development and Manufacturing Organization (CDMO)

Offers end-to-end CDMO support encompassing development, scale-up, manufacturing, and quality oversight.

Used when:

Programs require an integrated manufacturing partner
Development and commercial strategies must align
Long-term supply planning is a priority

Benefits of an Integrated Upstream & Downstream Partner

Continuity Across Development Stages: Avoids fragmentation and loss of process context between vendors or phases.
Reduced Regulatory and Technical Risk: Early alignment with quality expectations reduces surprises later.
Predictable Timelines: Integrated planning improves coordination and milestone execution.
Decision-Ready Outputs: Material and documentation are delivered with interpretation in mind, not just execution.

Representative Program Scenarios

The below scenarios illustrate how upstream and downstream process services are typically applied. These are general examples for illustration and do not reference specific clients.

Scenario 1: Preclinical Program Preparing for IND Submission

Program Background:

A biologics development program required early-stage material for functional characterization and proof-of-concept studies, followed by GLP toxicology material and eventual transition into cGMP manufacturing to support an IND submission.

At the outset, the client faced a familiar challenge: early material needs were immediate, but decisions made during this phase would directly affect the feasibility, cost, and timeline of later regulated manufacturing.

Key concerns included:

Avoiding repeated process redevelopment between non-regulated and regulated stages
Ensuring early material would be representative of future clinical batches
Maintaining data continuity across functional testing, toxicology, and manufacturing

Integrated Strategy:

Profacgen supported the program through a staged yet aligned approach:

Early non-cGMP and GLP-compliant production to support functional studies and toxicology, with upstream and downstream parameters selected based on scalability and regulatory compatibility
Upstream and downstream process planning conducted with future cGMP translation in mind, minimizing changes in expression systems, purification strategies, and critical process parameters
Analytical and QC method alignment, allowing early characterization data to inform later release testing requirements
Seamless transition into cGMP manufacturing, supported by established process knowledge, batch documentation, and regulatory-ready reporting

Throughout the program, manufacturing, QC, and documentation activities were managed within a unified framework to ensure consistency across development phases.

Program Outcome:

The client advanced from early functional studies to IND-enabling activities without significant process re-engineering or data loss. By integrating early-stage production with long-term regulatory objectives, the program achieved:

Reduced development risk during IND preparation
Shortened timelines between GLP studies and cGMP manufacturing
Increased confidence in regulatory interactions due to coherent process and data continuity

Scenario 2: Complex Protein with Solubility and Glycosylation Challenges

Program Background:

A complex recombinant protein exhibited low solubility and heterogeneous glycosylation, creating challenges for functional performance and manufacturability. The client required a solution that could address molecular complexity while maintaining a clear path toward regulated production.

Primary challenges included:

Expression primarily as inclusion bodies
Functional dependence on specific glycosylation patterns
Risk of extensive redevelopment when transitioning into regulated manufacturing

Integrated Strategy:

Profacgen implemented a coordinated development strategy combining multiple specialized capabilities:

Expression optimization and inclusion body purification, followed by controlled protein refolding to recover biologically active material
In Vitro Glyco Engineering (IVGE) to modulate glycosylation profiles and evaluate structure–function relationships under controlled conditions
Functional and analytical characterization to assess the impact of refolding and glyco-engineering on activity, stability, and consistency
Manufacturing pathway planning, ensuring that refolding and IVGE strategies were compatible with future scale-up and regulatory expectations

By addressing solubility, folding, and glycosylation challenges within an integrated framework, the program avoided fragmented experimentation and preserved a viable route to regulated manufacturing.

Program Outcome:

The client successfully identified a manufacturable and functionally optimized protein variant, supported by a scalable upstream and downstream strategy. As a result, the program achieved:

Improved functional performance with controlled molecular attributes
Reduced risk during scale-up and technology transfer
A clear and defensible path toward GLP and cGMP production

Discuss Your Project with Our Experts

Frequently Asked Questions (FAQs)

Q: What stages of development do your upstream and downstream services support?

A: Our upstream and downstream process services support biologics programs across the full development lifecycle, from early feasibility and non-cGMP production through GLP studies and into cGMP manufacturing. Processes are designed with scalability and regulatory compatibility in mind, allowing early-stage development work to transition smoothly into regulated manufacturing without extensive re-engineering.

Q: Can early-stage process development be directly translated into cGMP manufacturing?

A: Yes. A core objective of our upstream and downstream strategy is to maintain process continuity. Expression systems, purification schemes, refolding strategies, and critical process parameters are selected and documented to facilitate later cGMP translation, reducing the need for process redevelopment during scale-up or regulatory transition.

Q: Do you support difficult or non-standard proteins?

A: We routinely support proteins with increased development complexity, including:

Proteins expressed as inclusion bodies requiring purification and refolding
Molecules with solubility or stability challenges
Proteins requiring controlled post-translational modification, including glycosylation
Enzymes, antimicrobial peptides, and functional protein variants

Our upstream and downstream workflows are adapted based on molecular characteristics while remaining compatible with future regulatory requirements.

Q: How do you integrate upstream and downstream development with analytical and QC support?

A: Upstream and downstream activities are closely coordinated with analytical characterization and quality control testing. Process decisions are informed by analytical data, and QC methods are aligned early to ensure that material produced at different stages remains comparable and suitable for later release and stability testing.

Q: Can you support scale-up and large-scale production?

A: Yes. Our upstream and downstream process development services are structured to support scale-up from laboratory and pilot scales to large-scale production. Scale-up strategies are developed alongside purification and refolding workflows to maintain product quality, consistency, and process robustness at increased volumes.

Q: How early should clients engage upstream and downstream process development services?

A: Ideally, clients should engage upstream and downstream process development as early as possible, particularly when future IND-enabling or cGMP manufacturing is anticipated. Early alignment helps prevent downstream delays, reduces overall development cost, and preserves the value of early-stage data.

Q: Are your upstream and downstream processes compatible with GLP and cGMP requirements?

A: Yes. While early-stage development may be conducted under non-cGMP conditions, our process designs, documentation practices, and transition strategies are aligned with GLP and cGMP expectations. This ensures a smoother progression into regulated manufacturing and quality-controlled production.

Q: Can you customize upstream and downstream workflows for specific program needs?

A: All upstream and downstream workflows are customized based on program goals, molecular characteristics, and regulatory timelines. Rather than offering fixed packages, we work with clients to define a development pathway that balances speed, risk, and long-term manufacturability.

Q: How do we get started or evaluate whether our program is a good fit?

A: Clients typically begin with a technical and programmatic discussion to review molecular characteristics, development stage, and regulatory goals. Based on this evaluation, we propose an integrated upstream and downstream strategy aligned with both near-term deliverables and long-term manufacturing objectives.